Payment overview · 2025
General Payments
$1,389.06
82 reported records · 26 companies
Healthcare provider profile · identity verified
Denise Smith Kennedy, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUGUSTA, GA · NPI 1104867191
Verified facts
What the public records show
CMS Open Payments records show Denise Smith Kennedy, MD received $1,389.06 in general payments during 2025 across 82 reported records.
Novo Nordisk Inc accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $307.24 | 22.1% | 20 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $148.35 | 10.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $128.67 | 9.3% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.87 | 8.0% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $104.98 | 7.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.59 | 4.9% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $68.59 | 4.9% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $49.93 | 3.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.06 | 3.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.51 | 2.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.17 | 2.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.84 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.05 | 1.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.87 | 1.7% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $22.29 | 1.6% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $22.28 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.11 | 1.6% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $22.11 | 1.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.15 | 1.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.29 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.92 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.19 | 1.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.88 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.42 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.14 | 1.0% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $13.56 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,375.50 | 81 |
| Entertainment | $13.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $222.98 | 16 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $148.35 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $113.78 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $112.83 | 10 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $95.80 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $95.80 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $95.80 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $84.26 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.38 | 7 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $68.59 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $49.93 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.06 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.06 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.05 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 104 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 204 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 136 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 79 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
204 | 49 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
104 | 104 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
79 | 69 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
136 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1125 | 314 |
| Amlodipine Besylate | Amlodipine Besylate | 680 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 122 |
| Omeprazole | Omeprazole | 373 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 370 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 298 | 96 |
| Metformin Hcl Er | Metformin Hcl | 264 | 82 |
| Tramadol Hcl | Tramadol Hcl | 253 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 230 | 63 |
| Pregabalin | Pregabalin | 220 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 204 | 67 |
| Farxiga | Dapagliflozin Propanediol | 204 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 57 |
| Clonazepam | Clonazepam | 201 | 41 |
| Losartan Potassium | Losartan Potassium | 200 | 57 |
| Bupropion Xl | Bupropion Hcl | 185 | 47 |
| Famotidine | Famotidine | 181 | 61 |
| Ramipril | Ramipril | 174 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 166 | 48 |
| Gabapentin | Gabapentin | 165 | 53 |
| Lisinopril | Lisinopril | 165 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 164 | 52 |
| Alprazolam | Alprazolam | 143 | 32 |
| Ozempic | Semaglutide | 142 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 52 |
| Sertraline Hcl | Sertraline Hcl | 141 | 44 |
| Simvastatin | Simvastatin | 140 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 35 |
| Mounjaro | Tirzepatide | 136 | 26 |
| Spironolactone | Spironolactone | 136 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 135 | 37 |
| Jardiance | Empagliflozin | 131 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 54 |
| Carvedilol | Carvedilol | 125 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 34 |
| Furosemide | Furosemide | 114 | 40 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 113 | 30 |
| Metformin Hcl | Metformin Hcl | 107 | 32 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 104 | 104 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 34 |
| Trazodone Hcl | Trazodone Hcl | 98 | 32 |
| Meloxicam | Meloxicam | 96 | 36 |
| Potassium Chloride | Potassium Chloride | 96 | 32 |
| Estradiol | Estradiol | 95 | 33 |
| Alendronate Sodium | Alendronate Sodium | 94 | 29 |
| Montelukast Sodium | Montelukast Sodium | 94 | 29 |
| Eliquis | Apixaban | 90 | 21 |
| Lorazepam | Lorazepam | 87 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 79 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | suppressed |
| Allopurinol | Allopurinol | 66 | 20 |
| Ezetimibe | Ezetimibe | 64 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 63 | 22 |
| Meclizine Hcl | Meclizine Hcl | 60 | 24 |
| Ibandronate Sodium | Ibandronate Sodium | 59 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 18 |
| Atenolol | Atenolol | 54 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 24 |
| Aripiprazole | Aripiprazole | 51 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 30 |
| Temazepam | Temazepam | 51 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 11 |
| Topiramate | Topiramate | 50 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 13 |
| Donepezil Hcl | Donepezil Hcl | 49 | 12 |
| Prednisone | Prednisone | 46 | 38 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Dexamethasone | Dexamethasone | 44 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 13 |
| Valsartan | Valsartan | 43 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Celecoxib | Celecoxib | 42 | 13 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Mirtazapine | Mirtazapine | 41 | 15 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Eszopiclone | Eszopiclone | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Rybelsus | Semaglutide | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Tdvax | Tetanus, Diphtheria Tox,adult | 36 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 14 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 19 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | 13 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 12 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | 13 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 21 |
| Fluconazole | Fluconazole | 22 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 20 | 20 |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | 11 |
| Modafinil | Modafinil | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,389.06 · 82 records | Novo Nordisk Inc | ABRYSVO, APRETUDE, AREXVY, CAPLYTA, CLOTTRIEVER BOLD CATHETER, COMIRNATY, Cologuard Collection Kit, FARXIGA, GEMTESA, JARDIANCE, Kerendia, Korlym, LINZESS, MOUNJARO, NFC-700, NURTEC ODT, NUZYRA, OCT OPHTHALMOSCOPE, OTEZLA, Ozempic, PANORAMIC OPHTHALMOSCOPE, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, Senza, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, Veozah, WaveWriter Alpha Prime 16, Wegovy, XHANCE, XIFAXAN, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error